• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Number of NDA supplement (sNDA) reviews completed and signed off within the month

Dictionary: The number of sNDA and sBLA reviews, for therapeutic protein and monoclonal antibody products, completed and signed off by OBP within the month. Includes all IQA reviews, primary reviews, summary and/or executive reviews. These reviews evaluate the impact of manufacturing changes on the quality of marketed products. These reviews cover quality related aspects of safety including immunogenicity.


These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A2
Nov 2009N/A3
Dec 2009N/A0
Jan 2010N/A2
Feb 2010N/A2
Mar 2010N/A1
Apr 2010N/A0
May 2010N/A1
Jun 2010N/A1
Jul 2010N/A2
Aug 2010N/A3
Sep 2010N/A0

Number of BLA supplement (sBLA) reviews completed and signed off within the month

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A14
Nov 2009N/A11
Dec 2009N/A9
Jan 2010N/A7
Feb 2010N/A9
Mar 2010N/A10
Apr 2010N/A17
May 2010N/A10
Jun 2010N/A19
Jul 2010N/A9
Aug 2010N/A10
Sep 2010N/A12

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.